ABOUT US
Many people living with eczema feel trapped between flares and the treatments meant to control them. Topical steroids remain a mainstay of care, but long‑term or high‑potency use can lead to thinning skin, stretch marks, visible blood vessels, and other local damage, and some patients develop so‑called topical steroid withdrawal, with burning, intense redness, swelling, and peeling that can be worse than their original disease when steroids are stopped. Recent reviews describe TSW as a red, burning, painful dermatitis that may follow prolonged topical steroid use, leaving patients frustrated and searching for options that do not carry the same fear of rebound or long‑term skin damage
MOVING ECZEMA TREATMENT INTO ITS NEXT CHAPTER
On the other side, systemic and next‑generation therapies can introduce a different set of risks. Broad immunosuppressants such as methotrexate, cyclosporine, and systemic steroids affect the whole immune system and are associated with serious potential adverse effects, including infections, organ toxicity, metabolic complications, and increased cancer risk.
Targeted biologics and JAK inhibitors have improved efficacy for many, but meta‑analyses and cohort studies show an overall increased infection risk with these agents, including herpes and fungal infections in patients on JAK inhibitors and higher fungal infection rates across biologics as a class; JAK inhibitors in particular carry warnings for serious infections, blood clots, cardiovascular events, and malignancy.
That’s why Kynova Therapeutics is focused on developing the next generation of treatment that targets the root biology of atopic dermatitis rather than just managing flares. By designing injectable peptide candidates that directly address chronic inflammation, barrier dysfunction, and disrupted repair pathways, we aim to move beyond broad immunosuppression and towards a more precise, skin‑centric approach. Our goal is to build therapies that are grounded in the underlying mechanisms of disease and thoughtfully engineered for long‑term use, so patients can aspire to control that feels more effective, more sustainable, and less compromising than the options they face today